Amplion's Machine Learning Platform Accelerates Precision Medicine Collaboration

#artificialintelligence 

Amplion, a leading precision medicine intelligence company, has released Dx:Revenue, a groundbreaking software solution that enables test providers to identify ideal pharmaceutical partnership opportunities at the right time to advance precision medicine collaboration. Dx: Revenue is an extension of Amplion's core business intelligence platform that leverages proprietary machine learning to deliver tailored insights into pharma and test developer activities. The platform draws from more than 34 million evidence sources such as clinical trials, scientific publications, conference abstracts, FDA cleared and approved tests, lab developed tests, diagnostic and drug pipelines and more in real time, producing prioritized and timely partnering opportunities that are a precise match between a test provider's capabilities and pharma's specific needs. "Precision medicine has a problem," says Chris Capdevila, CEO, Amplion. "There is an insurmountable volume of information with the potential to drive the realization of precision medicine for patients, but accessing that information strategically, effectively and quickly to make the best pharma partnering decisions is beyond human scale. Our company was founded to address this issue by providing critical evidence-based intelligence that supports the strategic decisions pharmaceutical and test developers need to make to be successful."